Time to Make a Change

Assessing LDL-C Accurately in the Era of Modern Pharmacotherapeutics and Precision Medicine

Vincent A. Pallazola, Renato Quispe, Mohamed B. Elshazly, Rachit Vakil, Vasanth Sathiyakumar, Steven Jones, Seth Martin

Research output: Contribution to journalReview article

Abstract

Purpose of Review: The Friedewald equation for estimation of low-density lipoprotein cholesterol (LDL-C) was published in 1972 as an alternative to direct assessment by preparative ultracentrifugation. In this equation, very low-density lipoprotein is estimated by dividing triglycerides by a fixed factor (5 in mg/dL or 2.2 in mmol/L) and subtracting this term from non-high-density lipoprotein cholesterol (non-HDL-C). This method was derived in fasting samples from a small cohort of patients with primarily genetic dyslipidemias followed at the NIH. The method served well as the global standard for LDL-C estimation for decades, but is not well suited to modern clinical practice because it tends to underestimate LDL-C at low LDL-C and high triglyceride levels. The concern is that underestimation could lead to undertreatment in high-risk patients. Recent Findings: Derived from big data and now validated around the world, a novel LDL-C equation created at Johns Hopkins replaces the fixed factor seen in the classic equation with a patient-specific variable based on triglyceride and non-HDL-C levels. Summary: Given its superior accuracy in fasting and non-fasting populations alike, the novel equation is now the preferred method for LDL-C estimation and is being incorporated by leading clinical laboratories.

Original languageEnglish (US)
Article number26
JournalCurrent Cardiovascular Risk Reports
Volume12
Issue number11
DOIs
StatePublished - Nov 1 2018

Fingerprint

Precision Medicine
Modern 1601-history
LDL Cholesterol
Triglycerides
Fasting
VLDL Lipoproteins
Ultracentrifugation
Dyslipidemias
Population

Keywords

  • Cardiovascular prevention
  • Dyslipidemia
  • Friedewald equation
  • Lipid metabolism
  • Novel low-density lipoprotein equation
  • Precision medicine

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Time to Make a Change : Assessing LDL-C Accurately in the Era of Modern Pharmacotherapeutics and Precision Medicine. / Pallazola, Vincent A.; Quispe, Renato; Elshazly, Mohamed B.; Vakil, Rachit; Sathiyakumar, Vasanth; Jones, Steven; Martin, Seth.

In: Current Cardiovascular Risk Reports, Vol. 12, No. 11, 26, 01.11.2018.

Research output: Contribution to journalReview article

Pallazola, Vincent A. ; Quispe, Renato ; Elshazly, Mohamed B. ; Vakil, Rachit ; Sathiyakumar, Vasanth ; Jones, Steven ; Martin, Seth. / Time to Make a Change : Assessing LDL-C Accurately in the Era of Modern Pharmacotherapeutics and Precision Medicine. In: Current Cardiovascular Risk Reports. 2018 ; Vol. 12, No. 11.
@article{eb2f39273a654ed898a11b0c8b965640,
title = "Time to Make a Change: Assessing LDL-C Accurately in the Era of Modern Pharmacotherapeutics and Precision Medicine",
abstract = "Purpose of Review: The Friedewald equation for estimation of low-density lipoprotein cholesterol (LDL-C) was published in 1972 as an alternative to direct assessment by preparative ultracentrifugation. In this equation, very low-density lipoprotein is estimated by dividing triglycerides by a fixed factor (5 in mg/dL or 2.2 in mmol/L) and subtracting this term from non-high-density lipoprotein cholesterol (non-HDL-C). This method was derived in fasting samples from a small cohort of patients with primarily genetic dyslipidemias followed at the NIH. The method served well as the global standard for LDL-C estimation for decades, but is not well suited to modern clinical practice because it tends to underestimate LDL-C at low LDL-C and high triglyceride levels. The concern is that underestimation could lead to undertreatment in high-risk patients. Recent Findings: Derived from big data and now validated around the world, a novel LDL-C equation created at Johns Hopkins replaces the fixed factor seen in the classic equation with a patient-specific variable based on triglyceride and non-HDL-C levels. Summary: Given its superior accuracy in fasting and non-fasting populations alike, the novel equation is now the preferred method for LDL-C estimation and is being incorporated by leading clinical laboratories.",
keywords = "Cardiovascular prevention, Dyslipidemia, Friedewald equation, Lipid metabolism, Novel low-density lipoprotein equation, Precision medicine",
author = "Pallazola, {Vincent A.} and Renato Quispe and Elshazly, {Mohamed B.} and Rachit Vakil and Vasanth Sathiyakumar and Steven Jones and Seth Martin",
year = "2018",
month = "11",
day = "1",
doi = "10.1007/s12170-018-0590-9",
language = "English (US)",
volume = "12",
journal = "Current Cardiovascular Risk Reports",
issn = "1932-9520",
publisher = "Current Medicine Group",
number = "11",

}

TY - JOUR

T1 - Time to Make a Change

T2 - Assessing LDL-C Accurately in the Era of Modern Pharmacotherapeutics and Precision Medicine

AU - Pallazola, Vincent A.

AU - Quispe, Renato

AU - Elshazly, Mohamed B.

AU - Vakil, Rachit

AU - Sathiyakumar, Vasanth

AU - Jones, Steven

AU - Martin, Seth

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Purpose of Review: The Friedewald equation for estimation of low-density lipoprotein cholesterol (LDL-C) was published in 1972 as an alternative to direct assessment by preparative ultracentrifugation. In this equation, very low-density lipoprotein is estimated by dividing triglycerides by a fixed factor (5 in mg/dL or 2.2 in mmol/L) and subtracting this term from non-high-density lipoprotein cholesterol (non-HDL-C). This method was derived in fasting samples from a small cohort of patients with primarily genetic dyslipidemias followed at the NIH. The method served well as the global standard for LDL-C estimation for decades, but is not well suited to modern clinical practice because it tends to underestimate LDL-C at low LDL-C and high triglyceride levels. The concern is that underestimation could lead to undertreatment in high-risk patients. Recent Findings: Derived from big data and now validated around the world, a novel LDL-C equation created at Johns Hopkins replaces the fixed factor seen in the classic equation with a patient-specific variable based on triglyceride and non-HDL-C levels. Summary: Given its superior accuracy in fasting and non-fasting populations alike, the novel equation is now the preferred method for LDL-C estimation and is being incorporated by leading clinical laboratories.

AB - Purpose of Review: The Friedewald equation for estimation of low-density lipoprotein cholesterol (LDL-C) was published in 1972 as an alternative to direct assessment by preparative ultracentrifugation. In this equation, very low-density lipoprotein is estimated by dividing triglycerides by a fixed factor (5 in mg/dL or 2.2 in mmol/L) and subtracting this term from non-high-density lipoprotein cholesterol (non-HDL-C). This method was derived in fasting samples from a small cohort of patients with primarily genetic dyslipidemias followed at the NIH. The method served well as the global standard for LDL-C estimation for decades, but is not well suited to modern clinical practice because it tends to underestimate LDL-C at low LDL-C and high triglyceride levels. The concern is that underestimation could lead to undertreatment in high-risk patients. Recent Findings: Derived from big data and now validated around the world, a novel LDL-C equation created at Johns Hopkins replaces the fixed factor seen in the classic equation with a patient-specific variable based on triglyceride and non-HDL-C levels. Summary: Given its superior accuracy in fasting and non-fasting populations alike, the novel equation is now the preferred method for LDL-C estimation and is being incorporated by leading clinical laboratories.

KW - Cardiovascular prevention

KW - Dyslipidemia

KW - Friedewald equation

KW - Lipid metabolism

KW - Novel low-density lipoprotein equation

KW - Precision medicine

UR - http://www.scopus.com/inward/record.url?scp=85053378650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053378650&partnerID=8YFLogxK

U2 - 10.1007/s12170-018-0590-9

DO - 10.1007/s12170-018-0590-9

M3 - Review article

VL - 12

JO - Current Cardiovascular Risk Reports

JF - Current Cardiovascular Risk Reports

SN - 1932-9520

IS - 11

M1 - 26

ER -